Targeting DnaN for tuberculosis therapy using novel griselimycins
2015
The discovery of Streptomyces -produced streptomycin founded the age of tuberculosis therapy. Despite the subsequent development of a curative regimen for this disease, tuberculosis remains a worldwide problem, and the emergence of multidrug-resistant Mycobacterium tuberculosis has prioritized the need for new drugs. Here we show that new optimized derivatives from Streptomyces -derived griselimycin are highly active against M. tuberculosis , both in vitro and in vivo, by inhibiting the DNA polymerase sliding clamp DnaN. We discovered that resistance to griselimycins, occurring at very low frequency, is associated with amplification of a chromosomal segment containing dnaN , as well as the ori site. Our results demonstrate that griselimycins have high translational potential for tuberculosis treatment, validate DnaN as an antimicrobial target, and capture the process of antibiotic pressure-induced gene amplification.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
66
References
199
Citations
NaN
KQI